Rhenium-186-HEDP and Strontium-89-Chloride in Treatment of Metastatic Bone Pain
In 25 patients we investigated the influence of Re-186 or Sr-89 on pain relief, reduction of analgesic consumption, and impairment of bone marrow function. We calculated the blood clearance, the excretion rate in urine and the accumulation in the bone. Blood samples were drawn weekly for 6 weeks and counted. 66% of the patients were able to reduce their analgesic intake. 66% of the patients had a significant, 17% a minor improvement of life quality. No differences were observed between the results of Sr-89 and Re-186-therapy. The excretion rate of Re-186 in the urine was 59% of the administered activity within 48h. Platelets decreased to 134.000 ± 68.000//mm3 and leucocytes to 4.300 ± 2.000/mm3. The bone accumulation of Re-186 was 36 ± 6%, with 17 ± 4% in the metastases as an average.
KeywordsPain Relief Bone Metastasis Excretion Rate Blood Clearance Radionuclide Therapy
Unable to display preview. Download preview PDF.
- 1.Campa JA, Payne R. The managment of intractable bone pain: a clinician’s perspective. Sem. Nucl. Med. 1992; No. 1: 3–10Google Scholar
- 2.Hosain F, Spencer RP. Radiopharmaceutical for pallation of metastatic osseous lessions:biologic and physical background. Sem. Nucl. Med. 1992; No. 1: 11–16Google Scholar
- 4.Quility P, Kirk D, Bolger J, Dearnaly D. A comparison of the palliative effects of Strontium and external radiotherapy in metastatic prostata cancer. Radiother. Oncol. 1994; 33–40Google Scholar